Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
M Bonsignori, DC Montefiori, X Wu, X Chen… - Journal of …, 2012 - Am Soc Microbiol
M Bonsignori, DC Montefiori, X Wu, X Chen, KK Hwang, CY Tsao, DM Kozink, RJ Parks…
Journal of virology, 2012•Am Soc MicrobiolPlasma from a small subset of subjects chronically infected with HIV-1 shows remarkable
magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we
isolated two broadly neutralizing antibodies (bnAbs), CH01 and VRC-CH31, from two clonal
lineages of memory B cells with distinct specificities (variable loop 1 and 2 [V1V2]
conformational specificity and CD4-binding site specificity, respectively) that recapitulate
95% of CH0219 serum neutralization breadth. These data provide proof of concept for an …
magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we
isolated two broadly neutralizing antibodies (bnAbs), CH01 and VRC-CH31, from two clonal
lineages of memory B cells with distinct specificities (variable loop 1 and 2 [V1V2]
conformational specificity and CD4-binding site specificity, respectively) that recapitulate
95% of CH0219 serum neutralization breadth. These data provide proof of concept for an …
Abstract
Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we isolated two broadly neutralizing antibodies (bnAbs), CH01 and VRC-CH31, from two clonal lineages of memory B cells with distinct specificities (variable loop 1 and 2 [V1V2] conformational specificity and CD4-binding site specificity, respectively) that recapitulate 95% of CH0219 serum neutralization breadth. These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities.
American Society for Microbiology